Introducing NowSecure Network Broker

NowSecure Network Broker enables comprehensive security testing for applications that communicate with private, behind-the-firewall APIs. Network Broker is a lightweight agent deployed in your network that establishes an outbound-only, encrypted WireGuard tunnel between the internal environment and the NowSecure testing infrastructure. With Network Broker in place, NowSecure can capture and analyze the complete app-to-backend traffic flow, including calls to private API endpoints.

Many enterprise mobile apps do not only talk to public APIs. They call internal systems behind firewalls, VPNs, and private networks, systems that carry your most sensitive data and are intentionally isolated from the internet.

Contact your designated NowSecure Technical Account Manager or Salesperson to learn more about how to take advantage of this powerful new feature. 

Network Broker is included in the Enterprise Support Tier.

Why it matters

  • Complete Coverage for Every Enterprise App and internal pre-release candidates: Apps connecting to on-premises ERP systems, internal banking APIs, healthcare EHR platforms, field operations backends, VPN-protected endpoints or development endpoints can now be fully assessed, not deferred or excluded. 
  • Built to Pass the Enterprise Security Review: No inbound ports. No shared VPN credentials. No exposure of internal network topology. The outbound-only WireGuard model addresses the most common CISO objections before they’re raised, and the open source codebase gives security architects the transparency they need to approve deployment with confidence.
  • One-Time Setup, Continuous Coverage: Deployment is a lightweight broker binary, Docker container, or Helm chart. NowSecure handles hub configuration. Most customers are up and running in no time. After initial setup, every subsequent automated assessment of internal-API apps runs without additional configuration, delivering ongoing coverage on a continuously expanding app surface.

Comments

0 comments

Article is closed for comments.